Trying to Get a GLP-1 Covered: What Actually Decides It

Nobody denies you for the reason you expect

I assumed coverage was about whether I was heavy enough. It is not, or not mainly. It is about which words are on the prescription and which words are in your plan document, and those two things being matched by somebody at a desk.

That reframing saved me a lot of misplaced effort, so I am handing it over.

The word that decides it

Insurers do not cover a molecule. They cover an indication — an approved use.

That is why the same tirzepatide can be covered under one brand name for type 2 diabetes and refused under another for weight management. Nothing about the chemical changed. The line in the formulary did.

So before anything else, the useful question for your prescriber is which label they are writing, and the useful question for your plan is what it does with that specific word.

What prior authorization actually is

It is a form your clinician's office sends before the pharmacy will fill it, arguing you meet the plan's criteria. Mine took eleven days and two phone calls, and I only found out it existed when the pharmacy told me. It is not a judgment about you, and it is not personal, though it absolutely feels personal when it comes back denied.

What tends to be asked for: your BMI, any weight-related conditions, and often documentation that you tried something else first. That last one is called step therapy, and it is the part that surprises people — a plan can require a cheaper attempt before it will consider this one.

If it is denied, there is an appeal, and appeals are won more often than people expect because the first pass is frequently a paperwork mismatch rather than a real clinical objection. Ask the office to tell you the specific reason code. You cannot argue with "denied."

If you are on Medicare, there is a live program with an end date

This one is genuinely new and genuinely temporary, and both halves matter.

Medicare is running a GLP-1 Bridge: Wegovy and Zepbound for a $50 per month copay for eligible beneficiaries, running 1 July 2026 through 31 December 2027¹.

Two things to hold alongside that. First, eligibility runs through your provider attesting you meet clinical criteria — nobody here can tell you whether you qualify. Second, and this is the part that will catch people: the $50 does not count toward your Part D deductible or your annual out-of-pocket maximum. It sits outside the benefit, so it does not move you toward the cap the way your other drug spending does.

There is also a broader five-year BALANCE model behind it — but its Medicare Part D component was announced as indefinitely delayed in April 2026, so it is not something to plan around yet.

If you are on Medicaid, it depends on your state, and the map is shrinking

Coverage of GLP-1s for obesity is optional for states, and as of January 2026 only 13 state Medicaid programs covered them under fee-for-service — down from 16 the year before¹.

That decline is the part I would not have guessed, and I had assumed the map only ever grew. It is worth checking your own state rather than assuming last year's answer still holds.

What I would actually do, in order

1. 1.Ask your prescriber which indication they are writing for.
2. 2.Ask your plan — by phone, and write down who you spoke to — whether that indication is covered, and whether step therapy applies.
3. 3.If denied, get the reason code and appeal it. Do not restart the whole process somewhere else first.
4. 4.Only then price the cash route, at the dose you will end up on rather than the starting one.

Where this left me

Doing more admin than I wanted and less guessing than before. I cannot tell you your plan will cover this, and anyone who does is selling something. What I can tell you is that the fight is usually about vocabulary, and going in knowing that is worth more than going in hopeful.

None of this is medical, legal or insurance advice, and coverage rules change faster than any article can.

If coverage is not coming, the cash side is where I ended up looking, and the shapes differ more than the prices do. Collective is $59 a month plus a required $199 annual membership. Nova charges a $99 monthly membership on top of the medication. Believe Health will not show you any price until you have applied and been approved, and Solaya MD never publishes one at all.

The opposite approach exists too, and it is easier to budget against: AHBARx, Nex Gen Rx and Goldspan Health all price cash-pay up front, though Goldspan makes you click out to another storefront to see it, and Oria Meds advertises figures on its front page that do not appear on the plan menu.

MEDGm is the one I found that carries brand Wegovy, Zepbound and Ozempic next to a compounded line, though it prices the brand products as a membership plus a medication cost it never publishes — and quotes that membership at $99 on two of them and $171 on the third.